Daily Stock Analysis, BLPH, Bellerophon Therapeutics Inc, priceseries

Bellerophon Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
0.90
Close
1.08
High
1.13
Low
0.90
Previous Close
0.91
Daily Price Gain
0.17
YTD High
1.14
YTD High Date
Feb 14, 2017
YTD Low
0.52
YTD Low Date
Jan 3, 2017
YTD Price Change
0.54
YTD Gain
99.63%
52 Week High
4.58
52 Week High Date
Jun 9, 2016
52 Week Low
0.43
52 Week Low Date
Nov 30, 2016
52 Week Price Change
-1.19
52 Week Gain
-52.42%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 14. 2015
4.01
Aug 24. 2015
4.42
6 Trading Days
10.22%
Link
LONG
Aug 25. 2015
5.02
Aug 26. 2015
5.42
1 Trading Days
8.07%
Link
LONG
Mar 3. 2016
2.26
Mar 22. 2016
2.69
13 Trading Days
18.97%
Link
LONG
May 31. 2016
1.26
Jun 16. 2016
2.01
12 Trading Days
59.45%
Link
Company Information
Stock Symbol
BLPH
Exchange
NasdaqGM
Company URL
http://www.bellerophon.com
Company Phone
908-574-4770
CEO
Jonathan M. Peacock
Headquarters
New Jersey
Business Address
184 LIBERTY CORNER ROAD, SUITE 302, WARREN, NJ 07059
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001600132
About

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases.

Description

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Its product candidates include INOpulse, a pulsatile nitric oxide delivery device, which has completed Phase II clinical trials for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases; and bioabsorbable cardiac matrix, a medical device for the prevention of congestive heart failure. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.